HALIFAX—In the lead-up to some form of national pharmacare, the Trudeau government plans to launch a new national Canadian Drug Agency as policy central for the regulation of prescription drugs. Accommodating voices from patient communities will be a challenge, because health advocacy organizations have long made competing claims across a wide chasm. I’m cautiously hopeful that Team Trudeau will jettison a longstanding, dubious practice: soliciting input from patient advocacy groups funded by the pharmaceutical industry.
Enter your email address to
register a free account.